Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
作者信息
Previsdomini Marco, Graziano Elisa, Decosterd Laurent, Courlet Perrine, Perren Andreas, Ceschi Alessandro
机构信息
ICU, Ospedale Regionale Bellinzona e Valli, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Service of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
出版信息
Br J Clin Pharmacol. 2019 Jul;85(7):1616-1618. doi: 10.1111/bcp.13950. Epub 2019 May 3.
Abstract
摘要
相似文献
1
Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
Br J Clin Pharmacol. 2019 Jul;85(7):1616-1618. doi: 10.1111/bcp.13950. Epub 2019 May 3.
2
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):509-518. doi: 10.1111/bcpt.13035. Epub 2018 Jun 29.
3
Cluster of cases of high-dose rosuvastatin-associated rhabdomyolysis and recent reduction of rosuvastatin dose for Asians in other countries.
Hong Kong Med J. 2023 Oct;29(5):474. doi: 10.12809/hkmj2310943. Epub 2023 Sep 28.
4
Rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient: A missed opportunity for pharmacist involvement.
J Am Pharm Assoc (2003). 2024 May-Jun;64(3):102016. doi: 10.1016/j.japh.2024.01.012. Epub 2024 Jan 23.
5
Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
.
Int J Clin Pharmacol Ther. 2017 May;55(5):442-448. doi: 10.5414/CP202784.
6
Authors' reply to rosuvastatin and risk of acute pancreatitis.
Int J Cardiol. 2015 Jul 15;191:270. doi: 10.1016/j.ijcard.2015.04.252. Epub 2015 May 1.
7
Acute kidney injury and rhabdomyolysis due to ticagrelor and rosuvastatin.
Nurse Pract. 2021 Nov 1;46(11):12-16. doi: 10.1097/01.NPR.0000794540.96561.51.
8
Rosuvastatin-induced rhabdomyolysis due to medication errors.
Ceska Slov Farm. 2020 Spring;69(2):100-102.
9
Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature.
Am J Ther. 2022;29(6):e657-e661. doi: 10.1097/MJT.0000000000001325. Epub 2021 Jan 5.
10
Rosuvastatin-related rhabdomyolysis causing severe proximal paraparesis and acute kidney injury.
BMJ Case Rep. 2019 Oct 9;12(10):e229244. doi: 10.1136/bcr-2019-229244.
引用本文的文献
1
Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins.
Front Pharmacol. 2024 Jul 15;15:1393616. doi: 10.3389/fphar.2024.1393616. eCollection 2024.
2
Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report.
Eur Heart J Case Rep. 2022 Feb 22;6(3):ytac091. doi: 10.1093/ehjcr/ytac091. eCollection 2022 Mar.
3
A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan.
Diseases. 2019 May 14;7(2):38. doi: 10.3390/diseases7020038.
本文引用的文献
1
Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
J Clin Pharmacol. 2017 Oct;57(10):1305-1314. doi: 10.1002/jcph.931. Epub 2017 May 17.
2
Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Xenobiotica. 2018 Mar;48(3):300-313. doi: 10.1080/00498254.2017.1295171. Epub 2017 Mar 10.
3
Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model.
J Pharm Sci. 2017 May;106(5):1439-1451. doi: 10.1016/j.xphs.2017.01.007. Epub 2017 Jan 13.
4
Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman.
Drug Saf Case Rep. 2016 Dec;3(1):14. doi: 10.1007/s40800-016-0036-6.
5
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Eur J Clin Pharmacol. 2016 Sep;72(9):1065-73. doi: 10.1007/s00228-016-2072-7. Epub 2016 May 26.
6
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Cardiovasc Ther. 2016 Aug;34(4):191-8. doi: 10.1111/1755-5922.12183.
7
Impact of OATP transporters on pharmacokinetics.
Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25.
8
Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):35-40. doi: 10.1016/j.jchromb.2007.05.012. Epub 2007 May 26.
9
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Pharmacol Ther. 2006 Oct;112(1):71-105. doi: 10.1016/j.pharmthera.2006.03.003. Epub 2006 May 22.
10
Rhabdomyolysis: an evaluation of 475 hospitalized patients.
Medicine (Baltimore). 2005 Nov;84(6):377-385. doi: 10.1097/01.md.0000188565.48918.41.
Zotero 插件